3 results
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
Main objective of the trial is to determine the effect of individualizing the immunosuppressive therapy based on baseline immune-risk stratification according to 2 new biomarkers (d-sp ELISPOT IFN-γ and donor/recipient HLA Eplet Mismatch), in a…
To evaluate the feasibility of MCRRF therapy in women with persisting perineal pain after episiotomy. Collection of pilot data is essential in the preparation of a larger randomized-controlled trial that investigates the efficacy of MCRRF therapy.